Search

Your search keyword '"Mei, Matthew"' showing total 540 results
Start Over Author "Mei, Matthew"
540 results on '"Mei, Matthew"'

103. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers

Author

Wang, Michael L., primary, Barrientos, Jacqueline C., additional, Furman, Richard R., additional, Mei, Matthew, additional, Barr, Paul M., additional, Choi, Michael Y., additional, de Vos, Sven, additional, Kallam, Avyakta, additional, Patel, Krish, additional, Kipps, Thomas J., additional, Rule, Simon, additional, Flanders, Kate, additional, Jessen, Katti A., additional, Ren, Hong, additional, Riebling, Peter C., additional, Graham, Patricia, additional, King, Lydia, additional, Thurston, Archie W., additional, Sun, Michael, additional, Schmidt, Elizabeth M., additional, Lannutti, Brian J., additional, Johnson, David M., additional, Miller, Langdon L., additional, and Spurgeon, Stephen E., additional

Published
2022
Full Text
View/download PDF

104. The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Author

Mei, Matthew, primary, Pillai, Raju, additional, Kim, Soyoung, additional, Estrada-Merly, Noel, additional, Afkhami, Michelle, additional, Yang, Lixin, additional, Meng, Zhuo, additional, Sobecks, Ronald M., additional, Oran, Betul, additional, Scott, Bart L., additional, Saber, Wael, additional, and Nakamura, Ryotaro, additional

Published
2021
Full Text
View/download PDF

105. Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade

Author

Herrera, Alex F., primary, Chen, Lu, additional, Budde, L. Elizabeth, additional, Armenian, Saro, additional, Nikolaenko, Liana, additional, Chen, Robert, additional, Daniels, Shari, additional, Kennedy, Neena, additional, Peters, Lacolle, additional, Rosen, Steven T., additional, Forman, Stephen J, additional, Popplewell, Leslie L., additional, Kwak, Larry W., additional, and Mei, Matthew, additional

Published
2021
Full Text
View/download PDF

106. Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Author

Ahmed, Sairah, primary, Flinn, Ian W., additional, Mei, Matthew, additional, Riedell, Peter A., additional, Armand, Philippe, additional, Grover, Natalie S, additional, Engert, Andreas, additional, Lapteva, Natalia, additional, Nadler, Paul I., additional, Myo, Aung, additional, and Heslop, Helen E., additional

Published
2021
Full Text
View/download PDF

107. Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Author

Wang, Michael, primary, Mei, Matthew, additional, Barr, Paul M., additional, Barrientos, Jacqueline, additional, de Vos, Sven, additional, Furman, Richard, additional, Patel, Krish, additional, Thompson, Philip A., additional, Choi, Michael, additional, Kallam, Avyakta, additional, Zhu, Ying, additional, Chakraborty, Samhita, additional, Marinello, Patricia, additional, and Spurgeon, Stephen E., additional

Published
2021
Full Text
View/download PDF

108. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

Author

Aldoss, Ibrahim, primary, Yang, Dongyun, additional, Gu, Zhaohui, additional, Tomazian, Vanina, additional, Mokhtari, Sally, additional, Jackson, Ryan, additional, Telatar, Milhan, additional, Yew, Hooi, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Khaled, Samer, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Mei, Matthew, additional, Arslan, Shukaib, additional, Koller, Paul, additional, Artz, Andrew S., additional, Aoun, Patricia, additional, Gu, Dongqing, additional, Snyder, David S, additional, Stewart, F. Mark, additional, Curtin, Peter T., additional, Stein, Anthony S., additional, Pillai, Raju, additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Pullarkat, Vinod A., additional, Nakamura, Ryotaro, additional, and Afkhami, Michelle, additional

Published
2021
Full Text
View/download PDF

109. Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

Author

Gordon, Max J., primary, Kaempf, Andy, additional, Rotbain, Emelie, additional, Sitlinger, Andrea, additional, Shouse, Geoffrey, additional, Mei, Matthew, additional, Brander, Danielle M., additional, Salous, Tareq, additional, Hill, Brian T., additional, Choi, Michael, additional, Cohen, Jonathon B., additional, Stephens, Deborah M., additional, Persky, Dan O., additional, Patel, Krish, additional, Shadman, Mazyar, additional, Park, Byung, additional, Niemann, Carsten Utoft, additional, and Danilov, Alexey V., additional

Published
2021
Full Text
View/download PDF

110. Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Author

Horwitz, Steven M., primary, Foran, James M., additional, Maris, Michael, additional, Lue, Jennifer Kimberly, additional, Sawas, Ahmed, additional, Okada, Craig, additional, Feldman, Tatyana A., additional, Sokol, Lubomir, additional, Mei, Matthew, additional, Flinn, Ian W., additional, Villa, Diego, additional, Percival, Mary-Elizabeth M., additional, Jagadeesh, Deepa, additional, Savage, Kerry J., additional, Akilov, Oleg, additional, Diefenbach, Catherine S., additional, Kim, Youn H., additional, Lin, Gloria H. Y., additional, Catalano, Tina, additional, Petrova, Penka S., additional, Uger, Bob, additional, Molloy, Naomi, additional, Large, Kathleen, additional, Bruns, Ingmar, additional, and Ansell, Stephen M., additional

Published
2021
Full Text
View/download PDF

113. Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Author

Horwitz, Steven M., Foran, James M., Maris, Michael, Sawas, Ahmed, Okada, Craig, Feldman, Tatyana A., Minden, Mark D., Sokol, Lubomir, Mei, Matthew, Flinn, Ian W., Villa, Diego, Percival, Mary-Elizabeth M., Jagadeesh, Deepa, Savage, Kerry J., Akilov, Oleg E., Diefenbach, Catherine, Kim, Youn H., Lin, Gloria H.Y., Catalano, Tina, Petrova, Penka S., Uger, Bob, Molloy, Naomi, Large, Kathleen, Shou, Yaping, and Ansell, Stephen M.

Published
2020
Full Text
View/download PDF

115. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis

Author

Smith, Stephen D., primary, Lopedote, Paolo, additional, Samara, Yazeed, additional, Mei, Matthew, additional, Herrera, Alex F., additional, Winter, Allison M., additional, Hill, Brian T., additional, Shadman, Mazyar, additional, Ujjani, Chaitra, additional, Lynch, Ryan C., additional, Jacobson, Caron A., additional, Kim, Austin I., additional, Caimi, Paolo, additional, Milano, Filippo, additional, and Gopal, Ajay K., additional

Published
2021
Full Text
View/download PDF

116. Peri-Transplant Administration of Ruxolitinib (Rux) in Patients with Myelofibrosis (MF) Is Safe and Effective. A Pilot Study

Author

Ali, Haris, primary, Snyder, David S., additional, Tsia, Ni-Chun, additional, Synold, Timothy, additional, Mokhtari, Sally, additional, Palmer, Joycelynne, additional, Rahmanuddin, Syed, additional, Salhotra, Amandeep, additional, Pullarkat, Vinod, additional, Cai, Ji-Lian, additional, Forman, Stephen J., additional, Mei, Matthew, additional, and Nakamura, Ryotaro, additional

Published
2021
Full Text
View/download PDF

117. Avelumab (A) Plus Utomilumab (U) in Combination with RICE (rituximab, ifosfamide, carboplatin, etoposide) As a Second-Line Therapy for Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Author

Nikolaenko, Liana, primary, Chen, Lu, additional, Herrera, Alex F., additional, Budde, Lihua E., additional, Mei, Matthew, additional, Siddiqi, Tanya, additional, Chen, Robert, additional, Zain, Jasmine, additional, Kwak, Larry W., additional, Rosen, Steven, additional, and Popplewell, Leslie, additional

Published
2021
Full Text
View/download PDF

118. Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

Author

Aldoss, Ibrahim, primary, Afkhami, Michelle, additional, Yang, Dongyun, additional, Mokhtari, Sally, additional, Tomasian, Vanina, additional, Telatar, Milhan, additional, Yew, Hooi, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Khaled, Samer K., additional, Ali, Haris, additional, Mei, Matthew, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Koller, Paul, additional, Artz, Andrew S., additional, Aoun, Patricia, additional, Snyder, David S., additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Pillai, Raju, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Nakamura, Ryotaro, additional

Published
2021
Full Text
View/download PDF

120. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

Author

Jagadeesh, Deepa, Majhail, Navneet S., He, Yizeng, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Cairo, Mitchell, Cerny, Jan, Epperla, Narendranath, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Haverkos, Bradley, Hossain, Nasheed, Inwards, David, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard M., Lazaryan, Aleksandr, Lekakis, Lazaros, Mei, Matthew, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Geethakumari, Praveen Ramakrishnan, Savani, Bipin N., Yared, Jean A., Fenske, Timothy S., Kharfan-Dabaja, Mohamed A., Sureda, Anna, Hamadani, Mehdi, Jagadeesh, Deepa, Majhail, Navneet S., He, Yizeng, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Cairo, Mitchell, Cerny, Jan, Epperla, Narendranath, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Haverkos, Bradley, Hossain, Nasheed, Inwards, David, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard M., Lazaryan, Aleksandr, Lekakis, Lazaros, Mei, Matthew, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Geethakumari, Praveen Ramakrishnan, Savani, Bipin N., Yared, Jean A., Fenske, Timothy S., Kharfan-Dabaja, Mohamed A., Sureda, Anna, and Hamadani, Mehdi

Abstract

BACKGROUND Although rituximab-based high-dose therapy is frequently used in diffuse large B cell lymphoma (DLBCL) patients undergoing autologous hematopoietic cell transplantation (auto-HCT), data supporting the benefits are not available. Herein, we report the impact of rituximab-based conditioning on auto-HCT outcomes in patients who have DLBCL. METHODS Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, 862 adult DLBCL patients undergoing auto-HCT between 2003 and 2017 using BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning regimen were included. All patients received frontline rituximab-containing chemoimmunotherapy and had chemosensitive disease pre-HCT. Early chemoimmunotherapy failure was defined as not achieving complete remission (CR) after frontline chemoimmunotherapy or relapse within 1 year of initial diagnosis. The primary outcome was overall survival (OS). RESULTS The study cohort was divided into 2 groups: BEAM (n = 667) and R-BEAM (n = 195). On multivariate analysis, no significant difference was seen in OS (P = .83) or progression-free survival (PFS) (P = .61) across the 2 cohorts. No significant association between the use of rituximab and risk of relapse (P = .15) or nonrelapse mortality (P = .12) was observed. Variables independently associated with lower OS included older age at auto-HCT (P < .001), absence of CR at auto-HCT (P < .001) and early chemoimmunotherapy failure (P < .001). Older age (P < .0002) and non-CR pre-HCT (P < .0001) were also associated with inferior PFS. There was no significant difference in early infectious complications between the 2 cohorts. CONCLUSION In this large registry analysis of DLBCL patients undergoing auto-HCT, the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes. Older age, absence of CR pre auto-HCT, and early chemoimmunotherapy failure were associated with inferior survival.

Published
2020
Full Text
View/download PDF

121. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma

Author

Ahmed, Sairah, Ghosh, Nilanjan, Ahn, Kwang W., Khanal, Manoj, Litovich, Carlos, Mussetti, Alberto, Chhabra, Saurabh, Cairo, Mitchell, Mei, Matthew, William, Basem, Nathan, Sunita, Bejanyan, Nelli, Olsson, Richard, Dahi, Parastoo B., van der Poel, Marjolein, Steinberg, Amir, Kanakry, Jennifer, Cerny, Jan, Farooq, Umar, Seo, Sachiko, Kharfan-Dabaja, Mohamed A., Sureda, Anna, Fenske, Timothy S., Hamadani, Mehdi, Ahmed, Sairah, Ghosh, Nilanjan, Ahn, Kwang W., Khanal, Manoj, Litovich, Carlos, Mussetti, Alberto, Chhabra, Saurabh, Cairo, Mitchell, Mei, Matthew, William, Basem, Nathan, Sunita, Bejanyan, Nelli, Olsson, Richard, Dahi, Parastoo B., van der Poel, Marjolein, Steinberg, Amir, Kanakry, Jennifer, Cerny, Jan, Farooq, Umar, Seo, Sachiko, Kharfan-Dabaja, Mohamed A., Sureda, Anna, Fenske, Timothy S., and Hamadani, Mehdi

Abstract

Reduced-intensity conditioning (RIC) allogeneic haematopoietic cell transplantation (allo-HCT) is a curative option for select relapsed/refractory Hodgkin lymphoma (HL) patients; however, there are sparse data to support superiority of any particular conditioning regimen. We analyzed 492 adult patients undergoing human leucocyte antigen (HLA)-matched sibling or unrelated donor allo-HCT for HL between 2008 and 2016, utilizing RIC with either fludarabine/busulfan (Flu/Bu), fludarabine/melphalan (Flu/Mel140) or fludarabine/cyclophosphamide (Flu/Cy). Multivariable regression analysis was performed using a significance level of <0 center dot 01. There were no significant differences between regimens in risk for non-relapse mortality (NRM) (P = 0 center dot 54), relapse/progression (P = 0 center dot 02) or progression-free survival (PFS) (P = 0 center dot 14). Flu/Cy conditioning was associated with decreased risk of mortality in the first 11 months after allo-HCT (HR = 0 center dot 28; 95% CI = 0 center dot 10-0 center dot 73; P = 0 center dot 009), but beyond 11 months post allo-HCT it was associated with a significantly higher risk of mortality, (HR = 2 center dot 46; 95% CI = 0 center dot 1.32-4 center dot 61; P = 0 center dot 005). Four-year adjusted overall survival (OS) was similar across regimens at 62% for Flu/Bu, 59% for Flu/Mel140 and 55% for Flu/Cy (P = 0 center dot 64), respectively. These data confirm the choice of RIC for allo-HCT in HL does not influence risk of relapse, NRM or PFS. Although no OS benefit was seen between Flu/Bu and Flu/Mel 140; Flu/Cy was associated with a significantly higher risk of mortality beyond 11 months from allo-HCT (possibly due to late NRM events).

Published
2020
Full Text
View/download PDF

124. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Author

Ansell, Stephen M., primary, Maris, Michael B., additional, Lesokhin, Alexander M., additional, Chen, Robert W., additional, Flinn, Ian W., additional, Sawas, Ahmed, additional, Minden, Mark D., additional, Villa, Diego, additional, Percival, Mary-Elizabeth M., additional, Advani, Anjali S., additional, Foran, James M., additional, Horwitz, Steven M., additional, Mei, Matthew G., additional, Zain, Jasmine, additional, Savage, Kerry J., additional, Querfeld, Christiane, additional, Akilov, Oleg E., additional, Johnson, Lisa D.S., additional, Catalano, Tina, additional, Petrova, Penka S., additional, Uger, Robert A., additional, Sievers, Eric L., additional, Milea, Anca, additional, Roberge, Kathleen, additional, Shou, Yaping, additional, and O'Connor, Owen A., additional

Published
2021
Full Text
View/download PDF

125. Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Author

Herrera, Alex F., primary, Chen, Lu, additional, Nieto, Yago, additional, Holmberg, Leona, additional, Johnston, Patrick B., additional, Mei, Matthew, additional, Popplewell, Leslie, additional, Armenian, Saro H., additional, Cao, Thai, additional, Farol, Len, additional, Sahebi, Firoozeh, additional, Spielberger, Ricardo, additional, Chen, Robert, additional, Nademanee, Auayporn P., additional, Peters, Lacolle, additional, Kennedy, Neena, additional, Rosen, Steven T., additional, Kwak, Larry W, additional, Forman, Stephen J., additional, and Feldman, Tatyana A., additional

Published
2020
Full Text
View/download PDF

126. VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Author

Wang, Michael, primary, Barrientos, Jacqueline C., additional, Furman, Richard R., additional, Mei, Matthew, additional, Barr, Paul M., additional, Choi, Michael Y., additional, de Vos, Sven, additional, Kallam, Avyakta, additional, Patel, Krish, additional, Rule, Simon, additional, Flanders, Kate, additional, Jessen, Katti A., additional, Riebling, Peter C., additional, Graham, Patricia, additional, King, Lydia, additional, Schmidt, Elizabeth M., additional, Lannutti, Brian J., additional, Johnson, David M., additional, Miller, Langdon L., additional, and Spurgeon, Stephen E., additional

Published
2020
Full Text
View/download PDF

127. Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience

Author

Shouse, Geoffrey, primary, Cao, Thai, additional, Zhang, Jianying, additional, Mei, Matthew, additional, Herrera, Alex F., additional, Nikolaenko, Liana, additional, Zain, Jasmine, additional, Siddiqi, Tanya, additional, Popplewell, Leslie L., additional, Forman, Stephen J., additional, and Budde, Lihua E, additional

Published
2020
Full Text
View/download PDF

128. 498 - Real-World Outcomes of CD19 CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Diffuse Large B-Cell Lymphoma

Author

Kambhampati Thiruvengadam, Swetha, Popplewell, Leslie, Wang, Yan, Mei, Matthew, Nikolaenko, Liana, Shouse, Geoffrey, Herrera, Alex F., Zain, Jasmine, Siddiqi, Tanya, Godfrey, James, Baird, Dr. John H, Rosen, Steven, Danilov, Alexey V., Cai, Ji-Lian, Spielberger, Ricardo, Palmer, Joycelynne, Brown, Annette, Kwak, Larry W., Smith, Eileen, Forman, Stephen J., and Budde, L. Elizabeth E.

Published
2023
Full Text
View/download PDF

129. 133 - Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Author

Othman, Tamer, Koller, Paul, Tsai, Ni-Chun, Pourhassan, Hoda, Agrawal, Vaibhav, Otoukesh, Salman, Amanam, Idoroenyi, Ngo, Dat, Chen, Jason, Al Malki, Monzr M., Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Arslan, Shukaib, Ball, Brian, Stewart, Forrest, Curtin, Peter, Artz, Andrew S., Snyder, David S, Marcucci, Guido, Forman, Stephen J., Stein, Anthony S., Nakamura, Ryotaro, Pullarkat, Vinod, Aldoss, Ibrahim, and Mei, Matthew

Published
2023
Full Text
View/download PDF

131. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Author

Jacobson, Caron A., primary, Hunter, Bradley D., additional, Redd, Robert, additional, Rodig, Scott J., additional, Chen, Pei-Hsuan, additional, Wright, Kyle, additional, Lipschitz, Mikel, additional, Ritz, Jerome, additional, Kamihara, Yusuke, additional, Armand, Philippe, additional, Nikiforow, Sarah, additional, Rogalski, Michael, additional, Maakaron, Joseph, additional, Jaglowski, Samantha, additional, Maus, Marcela V., additional, Chen, Yi-Bin, additional, Abramson, Jeremy S., additional, Kline, Justin, additional, Budde, Elizabeth, additional, Herrera, Alex, additional, Mei, Matthew, additional, Cohen, Jonathon B., additional, Smith, Stephen D., additional, Maloney, David G., additional, Gopal, Ajay K., additional, Frigault, Matthew J., additional, and Acharya, Utkarsh H., additional

Published
2020
Full Text
View/download PDF

133. Venetoclax and hypomethylating agents inFLT3‐mutated acute myeloid leukemia

Author

Aldoss, Ibrahim, primary, Zhang, Jianying, additional, Mei, Matthew, additional, Al Malki, Monzr M, additional, Arslan, Shukaib, additional, Ngo, Dat, additional, Aribi, Ahmed, additional, Ali, Haris, additional, Sandhu, Karamjeet, additional, Salhotra, Amandeep, additional, Koller, Paul, additional, Khaled, Samer, additional, Artz, Andrew, additional, Snyder, David, additional, Nakamura, Ryotaro, additional, Forman, Stephen J, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, and Pullarkat, Vinod, additional

Published
2020
Full Text
View/download PDF

136. Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma

Author

Ahmed, Sairah, primary, Ghosh, Nilanjan, additional, Ahn, Kwang W., additional, Khanal, Manoj, additional, Litovich, Carlos, additional, Mussetti, Alberto, additional, Chhabra, Saurabh, additional, Cairo, Mitchell, additional, Mei, Matthew, additional, William, Basem, additional, Nathan, Sunita, additional, Bejanyan, Nelli, additional, Olsson, Richard F., additional, Dahi, Parastoo B., additional, Poel, Marjolein, additional, Steinberg, Amir, additional, Kanakry, Jennifer, additional, Cerny, Jan, additional, Farooq, Umar, additional, Seo, Sachiko, additional, Kharfan‐Dabaja, Mohamed A., additional, Sureda, Anna, additional, Fenske, Timothy S., additional, and Hamadani, Mehdi, additional

Published
2020
Full Text
View/download PDF

137. Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from Single Center.

Author

Salhotra, Amandeep, primary, Nikolaenko, Liana, additional, Chen, Lu, additional, Tsai, Ni-Chun, additional, Smith, D. Lynne, additional, Nademanee, Auayporn, additional, Popplewell, Leslie, additional, Herrera, Alex F., additional, Mei, Matthew, additional, Forman, Stephen J., additional, and Zain, Jasmine, additional

Published
2020
Full Text
View/download PDF

138. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma

Author

Chen, Robert, primary, Herrera, Alex F., additional, Hou, Jessie, additional, Chen, Lu, additional, Wu, Jun, additional, Guo, Yuming, additional, Synold, Timothy W., additional, Ngo, Vu N., additional, Puverel, Sandrine, additional, Mei, Matthew, additional, Popplewell, Leslie, additional, Yi, Shuhua, additional, Song, Joo Y., additional, Tao, Shu, additional, Wu, Xiwei, additional, Chan, Wing C., additional, Forman, Stephen J., additional, Kwak, Larry W., additional, Rosen, Steven T., additional, and Newman, Edward M., additional

Published
2020
Full Text
View/download PDF

139. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

Author

Jagadeesh, Deepa, primary, Majhail, Navneet S., additional, He, Yizeng, additional, Ahn, Kwang W., additional, Litovich, Carlos, additional, Ahmed, Sairah, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Badawy, Sherif M., additional, Bejanyan, Nelli, additional, Cairo, Mitchell, additional, Cerny, Jan, additional, Epperla, Narendranath, additional, Farhadfar, Nosha, additional, Freytes, César O., additional, Gale, Robert Peter, additional, Haverkos, Bradley, additional, Hossain, Nasheed, additional, Inwards, David, additional, Kamble, Rammurti T., additional, Kenkre, Vaishalee P., additional, Lazarus, Hillard M., additional, Lazaryan, Aleksandr, additional, Lekakis, Lazaros, additional, Mei, Matthew, additional, Murthy, Hemant S., additional, Mussetti, Alberto, additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Olsson, Richard F., additional, Ramakrishnan Geethakumari, Praveen, additional, Savani, Bipin N., additional, Yared, Jean A., additional, Fenske, Timothy S., additional, Kharfan‐Dabaja, Mohamed A., additional, Sureda, Anna, additional, and Hamadani, Mehdi, additional

Published
2020
Full Text
View/download PDF

140. Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Author

Salhotra, Amandeep, primary, Nikolaenko, Liana, additional, Chen, Lu, additional, Tsai, NI-Chun, additional, Smith, Diane Lynne, additional, Nademanee, Auayporn P., additional, Popplewell, Leslie L., additional, Herrera, Alex F., additional, Mei, Matthew, additional, Forman, Stephen J., additional, and Zain, Jasmine M., additional

Published
2019
Full Text
View/download PDF

142. Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Author

Salhotra, Amandeep, primary, Nikolaenko, Liana, additional, Chen, Lu, additional, Tsai, Ni-Chun, additional, Smith, Diane Lynne, additional, Nademanee, Auayporn P., additional, Popplewell, Leslie L., additional, Herrera, Alex F., additional, Mei, Matthew, additional, Aldoss, Ibrahim, additional, Pullarkat, Vinod A., additional, Forman, Stephen J., additional, and Zain, Jasmine M., additional

Published
2019
Full Text
View/download PDF

143. PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Author

Herrera, Alex F., primary, Chen, Robert W., primary, Palmer, Joycelynne, primary, Tsai, Ni-Chun, primary, Mei, Matthew, primary, Popplewell, Leslie L., primary, Nademanee, Auayporn P., primary, Nikolaenko, Liana, primary, McBride, Kathryn, primary, Ortega, Ricardo, primary, Song, Joo Y., primary, Rosen, Steven, primary, Kwak, Larry W, primary, Forman, Stephen J, primary, and Lee, Hun Ju, primary

Published
2019
Full Text
View/download PDF

145. Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Author

Herrera, Alex F., primary, Chen, Lu, primary, Popplewell, Leslie L., primary, Budde, Lihua E, primary, Mei, Matthew, primary, Armenian, Saro H., primary, Darrah, Justin, primary, Nikolaenko, Liana, primary, Chen, Robert W., primary, Peters, Lacolle, primary, Kennedy, Neena, primary, Rosen, Steven, primary, Forman, Stephen J, primary, and Kwak, Larry W, primary

Published
2019
Full Text
View/download PDF

146. Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Author

Ali, Haris, primary, Snyder, David, primary, Stiller, Tracy, primary, Synold, Timothy, primary, Mokhtari, Saloomeh, primary, Palmer, Joycelynne, primary, Salhotra, Amandeep, primary, Pullarkat, Vinod A., primary, Cai, Ji-lian, primary, Forman, Stephen J, primary, Mei, Matthew, primary, and Nakamura, Ryotaro, primary

Published
2019
Full Text
View/download PDF

147. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

Author

Gupta, Rohan, primary, Jamal, Faizi, additional, Yang, Dongyun, additional, Chendri, Chendri, additional, Aldoss, Ibrahim, additional, Malki, Monzr Al, additional, Mei, Matthew, additional, Salhotra, Amandeep, additional, Dobrin, Surime, additional, Tran, Michael, additional, Venkataraman, K., additional, Palmer, Joycelynne, additional, Stein, Anthony S., additional, Sandhu, Karamjeet, additional, Khaled, Samer, additional, Aribi, Ahmed, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Snyder, David, additional, Nakamura, Ryotaro, additional, Ali, Haris, additional, and Pullarkat, Vinod, additional

Published
2019
Full Text
View/download PDF

148. Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Author

Mei, Matthew G., Lee, Hun Ju, Palmer, Joycelynne M., Chen, Robert, Tsai, Ni-Chun, Chen, Lu, McBride, Kathryn, Smith, D. Lynne, Melgar, Ivana, Song, Joo Y., Bonjoc, Kimberley-Jane, Armenian, Saro, Nwangwu, Mary, Lee, Peter P., Zain, Jasmine, Nikolaenko, Liana, Popplewell, Leslie, Nademanee, Auayporn, Chaudhry, Ammar, Rosen, Steven, Kwak, Larry, Forman, Stephen J., and Herrera, Alex F.

Abstract

This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in relapsed/refractory (RR) classical Hodgkin lymphoma (cHL). Patients with RR cHL received 240 mg nivolumab every 2 weeks for up to 6 cycles (C). Patients in complete response (CR) after C6 proceeded to AHCT, whereas patients with progressive disease at any point or not in CR after C6 received NICE for 2 cycles. The primary endpoint was CR rate per the 2014 Lugano classification at completion of protocol therapy. Forty-three patients were evaluable for toxicity; 42 were evaluable for response. Thirty-four patients received nivolumab alone, and 9 patients received nivolumab+NICE. No unexpected toxicities were observed after nivolumab or NICE. After nivolumab, the overall response rate (ORR) was 81%, and the CR rate was 71%. Among 9 patients who received NICE, all responded, with 8 (89%) achieving CR. At the end of protocol therapy, the ORR and CR rates were 93% and 91%. Thirty-three patients were bridged directly to AHCT, including 26 after Nivo alone. The 2-year progression-free survival (PFS) and overall survival in all treated patients (n = 43) were 72% and 95%, respectively. Among 33 patients who bridged directly to AHCT, the 2-year PFS was 94% (95% CI: 78-98). PET-adapted sequential salvage therapy with nivolumab/nivolumab+NICE was well tolerated and effective, resulting in a high CR rate and bridging most patients to AHCT without chemotherapy. This trial was registered at www.clinicaltrials.gov #NCT03016871.

Published
2022
Full Text
View/download PDF

150. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Author

Ali, Haris, Tsai, Ni-Chun, Synold, Timothy, Mokhtari, Sally, Tsia, Weimin, Palmer, Joycelynne, Stiller, Tracey, Al Malki, Monzr, Aldoss, Ibrahim, Salhotra, Amandeep, Rahmanuddin, Syed, Pullarkat, Vinod, Cai, Ji-Lian, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Mei, Matthew, Snyder, David S., and Nakamura, Ryotaro

Abstract

We report results of our prospective pilot trial evaluating safety/feasibility of peritransplantation ruxolitinib for myelofibrosis treatment. Primary objectives were to determine safety and maximum tolerated dose (MTD) of ruxolitinib. Ruxolitinib was administered at 2 dose levels (DLs) of 5 and 10 mg twice daily, with fludarabine/melphalan conditioning regimen and tacrolimus/sirolimus graft-versus-host disease (GVHD) prophylaxis. We enrolled 6 and 12 patients at DL1 and DL2, respectively. Median age at transplantation was 65 years (range, 25-73). Per Dynamic International Prognostic Scoring System, 4 patients were high and 14 intermediate risk. Peripheral blood stem cells were graft source from matched sibling (n = 5) or unrelated (n = 13) donor. At each DL, 1 patient developed dose-limiting toxicities (DLTs): grade 3 cardiac and gastrointestinal with grade 4 pulmonary DLTs in DL1, and grade 3 kidney injury in DL2. All patients achieved engraftment. Grade 2 to 4 and 3 to 4 acute GVHD cumulative incidence was 17% (95% confidence interval [CI], 6-47) and 11% (95% CI, 3-41), respectively. Cumulative incidence of 1-year chronic GVHD was 42% (95% CI, 24-74). With 22.6-month (range, 6.2-25.8) median follow-up in surviving patients, 1-year overall and progression-free survival were 77% (95% CI, 50-91) and 71% (95% CI, 44-87), respectively. Causes of death (n = 4) were cardiac arrest, GVHD, respiratory failure, and refractory GVHD of liver. Our results show peritransplantation ruxolitinib is safe and well tolerated at MTD of 10 mg twice daily and associated with dose-dependent pharmacokinetic and cytokine profile. Early efficacy data are highly promising in high-risk older patients with myelofibrosis. This trial was registered at www.clinicaltrials.gov as #NCT02917096.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results